13F reference period
Q2 2026
Security Snapshot
Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) Institutional Ownership
CUSIP: 75383L102
13F Institutional Holders and Ownership History from Q2 2024 to Q3 2026
Institutions Reporting
160
Shares (Excl. Options)
51.27M
Full value: 51,271,114 · shares · 30 Jun 2026Price
$41.67
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- RAPP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 51,271,114
- Total 13F value
- $2,129,194,307
- Portfolio coverage rank
- 0.01%
- Share change
- -1,211,075
- Value change
- -$48,032,179
- Number of holders
- 160
- Shares outstanding
- 47,942,939
- SEC-reported price per share
- $33.60
- Insider filing price
- $33.60
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- RAPP - Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 75383L102.
- 160 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 146 to 160 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$1.64B
Full value: $1,641,485,641 · USD · 31 Mar 2026.$2.13B
Full value: $2,129,194,307 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 160 institutions filings for Q2 2026.
Security key
75383L102
13F reference period
Q2 2026
13F holders
160
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
RAPP full holder history
Rapport Therapeutics, Inc. SEC filings
Rapport Therapeutics, Inc. company facts
Rapport Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75383L102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
RAPP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 13% | -32% | $261,709,477 | -$35,615,682 | 6,280,525 | -12% | Third Rock Ventures V, L.P. | 30 Jun 2026 |
| Capital International Investors | 6.1% | $121,757,990 | 2,921,958 | Capital International Investors | 30 Jun 2026 | |||
| Cormorant Asset Management, LP | 5.6% | -10% | $110,738,900 | -$12,501,000 | 2,657,521 | -10% | Cormorant Asset Management, LP | 30 Jun 2026 |
| BlackRock, Inc. | 5% | $72,741,637 | 2,397,549 | BlackRock, Inc. | 31 Dec 2025 | |||
| Sofinnova Venture Partners XI, L.P. | 4.2% | $29,155,258 | 1,947,579 | Dr. James I. Healy ("Healy") | 11 Sep 2025 | |||
| JOHNSON & JOHNSON | 4.9% | $53,000,690 | 1,784,517 | JOHNSON & JOHNSON | 30 Sep 2025 |
As of 30 Jun 2026,
160
institutional investors reported holding
shares of
Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP).
This represents
107%
of the company’s total
outstanding shares.
51.27M
Full value: 51,271,114 · shares · 30 Jun 202647.94M
Full value: 47,942,939 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
94%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 7,172,894 | +0.06% | 0.01% | $298,894,493 |
| TRV GP V, LLC | 13% | 6,280,525 | -12% | 53% | $261,709,477 |
| ARCH Venture Management, LLC | 7.8% | 3,728,738 | 0% | 14% | $155,376,512 |
| Capital International Investors | 6.1% | 2,921,958 | -5.7% | 0.03% | $121,757,990 |
| GOLDMAN SACHS GROUP INC | 6.1% | 2,910,449 | -1.1% | 0.01% | $121,278,410 |
| BlackRock, Inc. | 5.6% | 2,699,786 | +7.7% | 0% | $112,500,083 |
| Cormorant Asset Management, LP | 5.5% | 2,657,521 | -10% | 5.7% | $110,738,900 |
| Sofinnova Investments, Inc. | 4% | 1,904,408 | 0% | 4.2% | $79,356,681 |
| JOHNSON & JOHNSON | 3.7% | 1,784,517 | 0% | 9.3% | $74,360,823 |
| Polar Capital Holdings Plc | 3.4% | 1,608,514 | -2.1% | 0.19% | $67,026,778 |
| BAKER BROS. ADVISORS LP | 3.2% | 1,547,090 | 0% | 0.32% | $64,467,240 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.8% | 1,346,512 | +1.6% | 0% | $56,109,155 |
| TRV GP VI, LLC | 2% | 969,218 | 0% | 17% | $40,387,314 |
| STATE STREET CORP | 1.7% | 818,712 | +7.8% | 0% | $34,115,729 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 793,453 | +10% | 0% | $33,068,458 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.6% | 787,446 | -9.1% | 0% | $32,814,000 |
| PERCEPTIVE ADVISORS LLC | 1.6% | 773,342 | +15% | 0.5% | $32,225,161 |
| Vestal Point Capital, LP | 1.5% | 730,000 | -49% | 0.71% | $30,419,100 |
| ALLIANCEBERNSTEIN L.P. | 1.4% | 693,384 | -4.7% | 0.01% | $21,695,985 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.3% | 644,082 | -30% | 0% | $26,838,898 |
| Siren, L.L.C. | 1.3% | 641,469 | 0% | 0.54% | $26,730,013 |
| Capital World Investors | 1.2% | 551,657 | +2.8% | 0% | $22,987,547 |
| T. Rowe Price Investment Management, Inc. | 0.82% | 393,200 | -37% | 0.01% | $16,385,000 |
| DIMENSIONAL FUND ADVISORS LP | 0.76% | 362,114 | +61% | 0% | $15,087,064 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.75% | 359,944 | +12% | 0% | $14,998,866 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Headline period
Q2 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 1,963,268 | $65,956,693 | -$1,183,931 | $33.60 | 22 |
| 2026 Q2 | 51,271,114 | $2,129,194,307 | -$48,032,179 | $41.67 | 160 |
| 2026 Q1 | 52,482,926 | $1,641,485,641 | +$41,369,429 | $31.29 | 146 |
| 2025 Q4 | 51,084,271 | $1,549,894,668 | +$54,540,100 | $30.34 | 144 |
| 2025 Q3 | 49,276,697 | $1,463,478,389 | +$335,895,056 | $29.70 | 123 |
| 2025 Q2 | 38,494,803 | $437,875,302 | +$4,896,059 | $11.37 | 81 |
| 2025 Q1 | 38,102,588 | $382,320,591 | +$11,241,443 | $10.03 | 77 |
| 2024 Q4 | 36,577,539 | $648,890,836 | -$29,671 | $17.74 | 69 |
| 2024 Q3 | 28,444,042 | $581,877,476 | +$37,552,009 | $20.48 | 55 |
| 2024 Q2 | 25,558,517 | $593,435,106 | +$593,435,106 | $23.26 | 35 |